Larimar Therapeutics Shares Soar 54% After Hours On CTI-1601 Update
11 Août 2022 - 11:39PM
Dow Jones News
By Kathryn Hardison
Larimar Therapeutics Inc. shares surged 54% to $3.05 in
after-hours trading on Thursday after it said provided updates
following a meeting with the Food and Drug Administration on the
CTI-1601 clinical program.
The company said it received feedback from the FDA on
information needed to resolve CTI-1601's current clinical hold, as
well as a proposed change for a second phase. CTI-1601 is a
treatment for Friedreich's ataxia.
Larimer plans to submit a complete response to CTI-1601's
clinical hold in the third quarter.
Larimar is also proposing a phase two, four-week dose
exploration study in Friedreich's ataxia patients. Friedreich's
ataxia is a rare disease that causes progressive nervous system
damage and movement problems, usually beginning during
childhood.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
August 11, 2022 17:24 ET (21:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Larimar Therapeutics (NASDAQ:LRMR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Larimar Therapeutics (NASDAQ:LRMR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
